Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Botswana | 140 | 2024 | 1040 | 4.660 |
Why?
|
HIV Infections | 166 | 2024 | 16715 | 4.110 |
Why?
|
HIV-1 | 78 | 2024 | 6939 | 3.040 |
Why?
|
Pregnancy Complications, Infectious | 41 | 2023 | 2026 | 2.220 |
Why?
|
Anti-HIV Agents | 54 | 2023 | 4255 | 2.150 |
Why?
|
Anti-Retroviral Agents | 32 | 2023 | 1714 | 1.880 |
Why?
|
Infectious Disease Transmission, Vertical | 28 | 2023 | 1320 | 1.530 |
Why?
|
HIV Seropositivity | 14 | 2023 | 971 | 1.340 |
Why?
|
Viral Load | 38 | 2023 | 3300 | 1.240 |
Why?
|
Antiretroviral Therapy, Highly Active | 31 | 2020 | 1872 | 1.240 |
Why?
|
Premature Birth | 16 | 2023 | 1721 | 1.120 |
Why?
|
Circumcision, Male | 6 | 2020 | 150 | 1.120 |
Why?
|
Drug Resistance, Viral | 15 | 2023 | 820 | 1.050 |
Why?
|
RNA, Viral | 26 | 2021 | 2901 | 1.020 |
Why?
|
Zidovudine | 17 | 2023 | 620 | 0.840 |
Why?
|
Breast Feeding | 16 | 2023 | 1338 | 0.770 |
Why?
|
Benzoxazines | 8 | 2020 | 301 | 0.770 |
Why?
|
Heterocyclic Compounds, 3-Ring | 5 | 2020 | 215 | 0.760 |
Why?
|
CD4 Lymphocyte Count | 30 | 2023 | 2560 | 0.740 |
Why?
|
Reverse Transcriptase Inhibitors | 8 | 2020 | 615 | 0.680 |
Why?
|
Nevirapine | 13 | 2023 | 267 | 0.660 |
Why?
|
Pregnancy Outcome | 17 | 2023 | 2795 | 0.640 |
Why?
|
HIV | 13 | 2022 | 1604 | 0.630 |
Why?
|
Hepatitis B | 5 | 2023 | 695 | 0.620 |
Why?
|
Pregnancy | 70 | 2023 | 29144 | 0.580 |
Why?
|
Stillbirth | 11 | 2023 | 346 | 0.560 |
Why?
|
Infant, Newborn | 50 | 2023 | 25628 | 0.500 |
Why?
|
HIV Antibodies | 13 | 2024 | 1322 | 0.480 |
Why?
|
Alkynes | 8 | 2020 | 306 | 0.420 |
Why?
|
Mass Screening | 6 | 2020 | 5253 | 0.410 |
Why?
|
Cyclopropanes | 8 | 2020 | 416 | 0.410 |
Why?
|
DNA, Viral | 11 | 2023 | 2227 | 0.400 |
Why?
|
Hepatitis B virus | 6 | 2023 | 513 | 0.390 |
Why?
|
Maternal-Fetal Exchange | 3 | 2018 | 456 | 0.390 |
Why?
|
HIV Integrase Inhibitors | 4 | 2021 | 142 | 0.390 |
Why?
|
Female | 148 | 2024 | 380193 | 0.380 |
Why?
|
Phylogeny | 13 | 2023 | 2804 | 0.370 |
Why?
|
Herpes Genitalis | 6 | 2011 | 140 | 0.370 |
Why?
|
Proviruses | 5 | 2023 | 318 | 0.360 |
Why?
|
Sexual Partners | 7 | 2018 | 729 | 0.360 |
Why?
|
Adult | 105 | 2023 | 214052 | 0.350 |
Why?
|
Child Development | 6 | 2019 | 2223 | 0.340 |
Why?
|
Infant Formula | 5 | 2021 | 199 | 0.340 |
Why?
|
Pregnancy Complications | 5 | 2023 | 2861 | 0.340 |
Why?
|
Humans | 184 | 2024 | 744366 | 0.340 |
Why?
|
Genotype | 16 | 2023 | 12952 | 0.340 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 393 | 0.340 |
Why?
|
Oxazines | 5 | 2020 | 298 | 0.320 |
Why?
|
Prenatal Exposure Delayed Effects | 6 | 2019 | 2408 | 0.300 |
Why?
|
Herpesvirus 2, Human | 6 | 2011 | 189 | 0.300 |
Why?
|
Mining | 1 | 2007 | 88 | 0.300 |
Why?
|
Pyridones | 6 | 2022 | 711 | 0.290 |
Why?
|
Milk, Human | 5 | 2012 | 490 | 0.290 |
Why?
|
Neural Tube Defects | 2 | 2019 | 256 | 0.280 |
Why?
|
Infant | 33 | 2023 | 35134 | 0.280 |
Why?
|
Acyclovir | 4 | 2011 | 272 | 0.280 |
Why?
|
Prevalence | 21 | 2023 | 15221 | 0.280 |
Why?
|
Disease Transmission, Infectious | 3 | 2019 | 547 | 0.280 |
Why?
|
Incidence | 15 | 2023 | 20952 | 0.260 |
Why?
|
Young Adult | 40 | 2022 | 56429 | 0.260 |
Why?
|
Wolves | 1 | 2023 | 9 | 0.230 |
Why?
|
Male | 82 | 2023 | 350115 | 0.220 |
Why?
|
Dog Diseases | 1 | 2023 | 138 | 0.210 |
Why?
|
Lamivudine | 4 | 2023 | 342 | 0.210 |
Why?
|
Dideoxynucleosides | 2 | 2012 | 122 | 0.210 |
Why?
|
Epidemics | 2 | 2022 | 523 | 0.190 |
Why?
|
Occupational Health | 1 | 2007 | 808 | 0.190 |
Why?
|
Hepatitis B Surface Antigens | 4 | 2023 | 305 | 0.190 |
Why?
|
Leukocytes, Mononuclear | 3 | 2023 | 1837 | 0.180 |
Why?
|
Rotavirus Vaccines | 1 | 2020 | 61 | 0.180 |
Why?
|
HIV Reverse Transcriptase | 2 | 2019 | 213 | 0.180 |
Why?
|
Postpartum Period | 4 | 2017 | 1086 | 0.180 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2014 | 657 | 0.180 |
Why?
|
Mothers | 5 | 2024 | 2165 | 0.180 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 222 | 0.180 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2020 | 127 | 0.170 |
Why?
|
Disease Reservoirs | 1 | 2019 | 131 | 0.170 |
Why?
|
Piperazines | 5 | 2020 | 2488 | 0.170 |
Why?
|
HIV Antigens | 2 | 2018 | 347 | 0.170 |
Why?
|
Vaccines, Conjugate | 1 | 2020 | 333 | 0.170 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 3 | 2023 | 371 | 0.170 |
Why?
|
HIV Seronegativity | 2 | 2011 | 211 | 0.170 |
Why?
|
Hepatitis B Antibodies | 3 | 2023 | 159 | 0.170 |
Why?
|
Paternal Exposure | 1 | 2019 | 89 | 0.170 |
Why?
|
Quarantine | 1 | 2020 | 170 | 0.160 |
Why?
|
Drug Therapy, Combination | 11 | 2019 | 6489 | 0.160 |
Why?
|
Adolescent | 26 | 2023 | 85779 | 0.160 |
Why?
|
Obstetric Labor, Premature | 1 | 2020 | 279 | 0.160 |
Why?
|
Mutation | 10 | 2023 | 29786 | 0.160 |
Why?
|
Tuberculosis | 3 | 2019 | 1912 | 0.150 |
Why?
|
Virus Activation | 1 | 2019 | 319 | 0.150 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 468 | 0.150 |
Why?
|
Transients and Migrants | 1 | 2020 | 155 | 0.150 |
Why?
|
Pneumococcal Vaccines | 1 | 2020 | 391 | 0.150 |
Why?
|
Antiviral Agents | 5 | 2022 | 2987 | 0.150 |
Why?
|
Syphilis | 1 | 2019 | 227 | 0.140 |
Why?
|
Receptors, CXCR4 | 2 | 2012 | 727 | 0.140 |
Why?
|
Gestational Age | 2 | 2018 | 3493 | 0.140 |
Why?
|
Disease Progression | 8 | 2017 | 13286 | 0.140 |
Why?
|
Enzyme Assays | 1 | 2017 | 111 | 0.140 |
Why?
|
Pyridazines | 1 | 2018 | 202 | 0.140 |
Why?
|
Genes, env | 2 | 2013 | 95 | 0.140 |
Why?
|
Diarrhea, Infantile | 1 | 2016 | 109 | 0.140 |
Why?
|
Middle Aged | 37 | 2021 | 213390 | 0.140 |
Why?
|
Fetus | 2 | 2020 | 1880 | 0.140 |
Why?
|
Cervix Uteri | 1 | 2020 | 590 | 0.140 |
Why?
|
Rural Population | 4 | 2019 | 2207 | 0.140 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2014 | 2232 | 0.140 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 294 | 0.130 |
Why?
|
Antibody Affinity | 1 | 2016 | 254 | 0.130 |
Why?
|
Serologic Tests | 1 | 2018 | 374 | 0.130 |
Why?
|
Congenital Abnormalities | 2 | 2019 | 707 | 0.130 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2019 | 3922 | 0.130 |
Why?
|
Antimalarials | 1 | 2022 | 905 | 0.130 |
Why?
|
Treatment Failure | 6 | 2021 | 2618 | 0.130 |
Why?
|
Antibodies, Neutralizing | 5 | 2024 | 1978 | 0.130 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2021 | 489 | 0.130 |
Why?
|
Pregnancy, Unplanned | 1 | 2016 | 95 | 0.130 |
Why?
|
Asymptomatic Infections | 1 | 2015 | 128 | 0.130 |
Why?
|
Nervous System | 1 | 2018 | 554 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1161 | 0.120 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2017 | 317 | 0.120 |
Why?
|
Child | 17 | 2024 | 77709 | 0.120 |
Why?
|
Contraception Behavior | 1 | 2016 | 185 | 0.120 |
Why?
|
Diarrhea | 1 | 2020 | 1348 | 0.120 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2023 | 4386 | 0.110 |
Why?
|
Deficiency Diseases | 1 | 2013 | 72 | 0.110 |
Why?
|
Travel | 1 | 2019 | 788 | 0.110 |
Why?
|
Pregnant Women | 3 | 2023 | 568 | 0.110 |
Why?
|
Hepatitis B e Antigens | 2 | 2023 | 133 | 0.110 |
Why?
|
AIDS Serodiagnosis | 2 | 2020 | 184 | 0.110 |
Why?
|
Respiratory System | 1 | 2016 | 557 | 0.110 |
Why?
|
Vaccination | 2 | 2023 | 3279 | 0.110 |
Why?
|
Causality | 1 | 2019 | 1275 | 0.110 |
Why?
|
Immunoassay | 1 | 2016 | 752 | 0.110 |
Why?
|
Malaria | 1 | 2022 | 1239 | 0.110 |
Why?
|
Immunity, Innate | 3 | 2022 | 2962 | 0.110 |
Why?
|
Prenatal Care | 1 | 2020 | 1092 | 0.110 |
Why?
|
Hypertension | 3 | 2023 | 8479 | 0.110 |
Why?
|
Mastitis | 1 | 2012 | 41 | 0.110 |
Why?
|
Early Diagnosis | 1 | 2017 | 1184 | 0.100 |
Why?
|
Plasma | 1 | 2015 | 575 | 0.100 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7182 | 0.100 |
Why?
|
Amino Acid Substitution | 3 | 2011 | 1793 | 0.100 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 12356 | 0.100 |
Why?
|
HIV Envelope Protein gp120 | 3 | 2016 | 952 | 0.100 |
Why?
|
Viremia | 3 | 2023 | 736 | 0.100 |
Why?
|
Counseling | 2 | 2022 | 1523 | 0.100 |
Why?
|
Birth Weight | 3 | 2023 | 2069 | 0.100 |
Why?
|
Placental Insufficiency | 1 | 2012 | 51 | 0.100 |
Why?
|
Hemoglobins | 1 | 2018 | 1532 | 0.100 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3177 | 0.100 |
Why?
|
Hospitalization | 6 | 2021 | 10259 | 0.100 |
Why?
|
Infant, Small for Gestational Age | 3 | 2021 | 440 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 602 | 0.100 |
Why?
|
Equipment and Supplies | 1 | 2014 | 281 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2018 | 1530 | 0.100 |
Why?
|
Evolution, Molecular | 2 | 2011 | 1939 | 0.100 |
Why?
|
Cross-Sectional Studies | 11 | 2023 | 25039 | 0.100 |
Why?
|
Attitude to Health | 1 | 2020 | 2052 | 0.100 |
Why?
|
Selenium | 1 | 2013 | 405 | 0.090 |
Why?
|
Carotid Artery Diseases | 1 | 2017 | 879 | 0.090 |
Why?
|
Immunoglobulin M | 3 | 2023 | 1537 | 0.090 |
Why?
|
Condoms | 3 | 2022 | 323 | 0.090 |
Why?
|
Developmental Disabilities | 2 | 2016 | 1456 | 0.090 |
Why?
|
Drug Resistance, Bacterial | 1 | 2017 | 1035 | 0.090 |
Why?
|
AIDS Vaccines | 1 | 2016 | 938 | 0.090 |
Why?
|
Didanosine | 1 | 2009 | 153 | 0.080 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1257 | 0.080 |
Why?
|
Drug Administration Schedule | 5 | 2018 | 4933 | 0.080 |
Why?
|
Valine | 1 | 2011 | 413 | 0.080 |
Why?
|
Cytokines | 2 | 2015 | 7323 | 0.080 |
Why?
|
Prospective Studies | 13 | 2023 | 53290 | 0.080 |
Why?
|
Mutation, Missense | 3 | 2013 | 2566 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2022 | 3864 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1178 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2019 | 7785 | 0.080 |
Why?
|
Alphapapillomavirus | 1 | 2011 | 221 | 0.080 |
Why?
|
Cohort Studies | 13 | 2021 | 40559 | 0.080 |
Why?
|
Intention to Treat Analysis | 3 | 2016 | 426 | 0.080 |
Why?
|
Longitudinal Studies | 8 | 2020 | 13991 | 0.080 |
Why?
|
Sequence Analysis, DNA | 7 | 2015 | 4805 | 0.080 |
Why?
|
Case-Control Studies | 8 | 2021 | 21748 | 0.080 |
Why?
|
Directive Counseling | 1 | 2009 | 166 | 0.080 |
Why?
|
Health Services Research | 2 | 2019 | 1836 | 0.080 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2011 | 387 | 0.080 |
Why?
|
Receptors, Cell Surface | 1 | 2017 | 2865 | 0.080 |
Why?
|
Hospitals, District | 2 | 2019 | 106 | 0.080 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2014 | 810 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2602 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 6 | 2016 | 6539 | 0.070 |
Why?
|
Risk Factors | 16 | 2020 | 72296 | 0.070 |
Why?
|
Child, Preschool | 9 | 2022 | 41005 | 0.070 |
Why?
|
Antigens, CD | 1 | 2017 | 4026 | 0.070 |
Why?
|
Dietary Supplements | 2 | 2022 | 3296 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2021 | 9274 | 0.070 |
Why?
|
Patient Compliance | 5 | 2010 | 2684 | 0.070 |
Why?
|
Acidosis, Lactic | 1 | 2007 | 142 | 0.070 |
Why?
|
Africa | 3 | 2017 | 672 | 0.070 |
Why?
|
Nitriles | 2 | 2023 | 955 | 0.070 |
Why?
|
Genetic Linkage | 1 | 2011 | 2421 | 0.070 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 39 | 0.070 |
Why?
|
Social Perception | 1 | 2009 | 425 | 0.070 |
Why?
|
Retrospective Studies | 12 | 2023 | 77460 | 0.060 |
Why?
|
Truth Disclosure | 1 | 2009 | 436 | 0.060 |
Why?
|
Vitamins | 1 | 2013 | 1623 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1343 | 0.060 |
Why?
|
Models, Statistical | 1 | 2020 | 5101 | 0.060 |
Why?
|
Stereotyping | 1 | 2006 | 241 | 0.060 |
Why?
|
Population Surveillance | 3 | 2019 | 2616 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2021 | 12025 | 0.060 |
Why?
|
Pneumonia | 1 | 2016 | 2133 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 2 | 2020 | 783 | 0.060 |
Why?
|
Pregnancy Rate | 1 | 2007 | 643 | 0.060 |
Why?
|
Neonatal Screening | 2 | 2020 | 591 | 0.060 |
Why?
|
Hepatitis Delta Virus | 1 | 2023 | 18 | 0.060 |
Why?
|
Time Factors | 9 | 2019 | 40075 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5135 | 0.060 |
Why?
|
Pre-Eclampsia | 1 | 2013 | 1200 | 0.060 |
Why?
|
Environmental Exposure | 1 | 2018 | 4232 | 0.060 |
Why?
|
Hepatitis B Core Antigens | 1 | 2023 | 92 | 0.060 |
Why?
|
Parturition | 2 | 2019 | 441 | 0.060 |
Why?
|
Tropism | 1 | 2023 | 41 | 0.060 |
Why?
|
Heterosexuality | 2 | 2019 | 276 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2013 | 3203 | 0.060 |
Why?
|
RNA | 2 | 2023 | 2749 | 0.060 |
Why?
|
Diketopiperazines | 1 | 2022 | 20 | 0.050 |
Why?
|
HIV Protease Inhibitors | 2 | 2018 | 430 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
Infant Mortality | 3 | 2014 | 754 | 0.050 |
Why?
|
Withholding Treatment | 2 | 2019 | 599 | 0.050 |
Why?
|
Viral Tropism | 1 | 2023 | 101 | 0.050 |
Why?
|
Microbial Sensitivity Tests | 2 | 2018 | 1877 | 0.050 |
Why?
|
Genome, Viral | 2 | 2020 | 667 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2133 | 0.050 |
Why?
|
Anemia | 1 | 2011 | 1503 | 0.050 |
Why?
|
Workplace | 1 | 2007 | 836 | 0.050 |
Why?
|
Americas | 1 | 2021 | 111 | 0.050 |
Why?
|
Chloroquine | 1 | 2022 | 279 | 0.050 |
Why?
|
Feces | 2 | 2017 | 1401 | 0.050 |
Why?
|
Vitamin D | 1 | 2014 | 3224 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 2 | 2014 | 3020 | 0.050 |
Why?
|
Treatment Outcome | 11 | 2018 | 63107 | 0.050 |
Why?
|
E-Selectin | 1 | 2023 | 579 | 0.050 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2023 | 707 | 0.050 |
Why?
|
Databases, Nucleic Acid | 1 | 2021 | 211 | 0.040 |
Why?
|
Immunoenzyme Techniques | 2 | 2013 | 1799 | 0.040 |
Why?
|
Maternal Mortality | 1 | 2022 | 310 | 0.040 |
Why?
|
Cervical Length Measurement | 1 | 2020 | 41 | 0.040 |
Why?
|
Papillomavirus Infections | 1 | 2011 | 1587 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2018 | 2715 | 0.040 |
Why?
|
Placenta | 2 | 2023 | 1699 | 0.040 |
Why?
|
Micronutrients | 1 | 2022 | 375 | 0.040 |
Why?
|
Pyrimidines | 2 | 2023 | 2943 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2023 | 1159 | 0.040 |
Why?
|
Monocytes | 2 | 2019 | 2596 | 0.040 |
Why?
|
Neutropenia | 2 | 2017 | 895 | 0.040 |
Why?
|
Anthropometry | 2 | 2016 | 1350 | 0.040 |
Why?
|
Nucleosides | 1 | 2019 | 138 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14723 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39052 | 0.040 |
Why?
|
Molecular Sequence Data | 4 | 2013 | 18111 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 724 | 0.040 |
Why?
|
Contact Tracing | 1 | 2020 | 273 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7721 | 0.040 |
Why?
|
Dogs | 1 | 2023 | 3912 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 9955 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2019 | 457 | 0.040 |
Why?
|
Selection Bias | 1 | 2019 | 371 | 0.040 |
Why?
|
Biometry | 1 | 2020 | 558 | 0.040 |
Why?
|
Government Programs | 1 | 2019 | 275 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2015 | 5321 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 816 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 1 | 2020 | 732 | 0.040 |
Why?
|
Thailand | 1 | 2017 | 296 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3395 | 0.040 |
Why?
|
Epitopes | 1 | 2023 | 2571 | 0.040 |
Why?
|
Qualitative Research | 2 | 2019 | 2682 | 0.030 |
Why?
|
Fetal Death | 1 | 2018 | 448 | 0.030 |
Why?
|
Inpatients | 2 | 2019 | 2518 | 0.030 |
Why?
|
Bayes Theorem | 2 | 2017 | 2307 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5388 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2017 | 418 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10252 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1608 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1768 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2020 | 2256 | 0.030 |
Why?
|
Folic Acid | 1 | 2022 | 1300 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 17446 | 0.030 |
Why?
|
United Nations | 1 | 2016 | 165 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2017 | 592 | 0.030 |
Why?
|
Escherichia coli | 2 | 2017 | 4217 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 1958 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9688 | 0.030 |
Why?
|
Base Sequence | 2 | 2019 | 12797 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2022 | 1240 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 847 | 0.030 |
Why?
|
World Health Organization | 1 | 2020 | 1318 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3338 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2017 | 862 | 0.030 |
Why?
|
Immunization, Passive | 1 | 2016 | 623 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 856 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 850 | 0.030 |
Why?
|
Iron | 1 | 2022 | 1774 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 640 | 0.030 |
Why?
|
Brazil | 1 | 2017 | 1270 | 0.030 |
Why?
|
Contraceptives, Oral | 1 | 2016 | 564 | 0.030 |
Why?
|
Intention | 1 | 2016 | 342 | 0.030 |
Why?
|
Social Stigma | 1 | 2019 | 701 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2015 | 323 | 0.030 |
Why?
|
Virus Replication | 1 | 2021 | 2535 | 0.030 |
Why?
|
Ultrasonography, Prenatal | 1 | 2020 | 1695 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 3873 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 639 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12244 | 0.030 |
Why?
|
Caregivers | 1 | 2024 | 2095 | 0.030 |
Why?
|
Gene Frequency | 1 | 2019 | 3587 | 0.030 |
Why?
|
Birth Certificates | 1 | 2011 | 67 | 0.030 |
Why?
|
Pregnancy Proteins | 1 | 2013 | 229 | 0.030 |
Why?
|
Specimen Handling | 1 | 2016 | 694 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2021 | 2047 | 0.030 |
Why?
|
India | 1 | 2017 | 2197 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 7914 | 0.020 |
Why?
|
Geography | 1 | 2013 | 669 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1049 | 0.020 |
Why?
|
Genetic Variation | 2 | 2019 | 6542 | 0.020 |
Why?
|
Algorithms | 3 | 2020 | 13882 | 0.020 |
Why?
|
Placebos | 1 | 2015 | 1676 | 0.020 |
Why?
|
Family Characteristics | 1 | 2016 | 1000 | 0.020 |
Why?
|
Community Health Services | 1 | 2016 | 650 | 0.020 |
Why?
|
Health Personnel | 2 | 2020 | 3219 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2020 | 6171 | 0.020 |
Why?
|
Goals | 1 | 2016 | 707 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1338 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5077 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2012 | 498 | 0.020 |
Why?
|
Lactation | 1 | 2012 | 412 | 0.020 |
Why?
|
Developing Countries | 2 | 2015 | 2815 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2012 | 13814 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 552 | 0.020 |
Why?
|
Neoplasms | 2 | 2015 | 21696 | 0.020 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2012 | 347 | 0.020 |
Why?
|
Body Height | 1 | 2016 | 1578 | 0.020 |
Why?
|
Perinatal Care | 1 | 2011 | 227 | 0.020 |
Why?
|
Sex Factors | 2 | 2014 | 10400 | 0.020 |
Why?
|
Seasons | 1 | 2014 | 1493 | 0.020 |
Why?
|
Spouses | 1 | 2011 | 286 | 0.020 |
Why?
|
Health Care Costs | 1 | 2022 | 3208 | 0.020 |
Why?
|
Sequence Homology | 1 | 2008 | 203 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2013 | 643 | 0.020 |
Why?
|
Virus Internalization | 1 | 2012 | 502 | 0.020 |
Why?
|
Kenya | 1 | 2011 | 685 | 0.020 |
Why?
|
Capsid Proteins | 1 | 2011 | 479 | 0.020 |
Why?
|
Unsafe Sex | 1 | 2010 | 220 | 0.020 |
Why?
|
Body Size | 1 | 2011 | 461 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2012 | 2839 | 0.020 |
Why?
|
Blood Pressure | 1 | 2023 | 8551 | 0.020 |
Why?
|
Peru | 1 | 2011 | 881 | 0.020 |
Why?
|
Campylobacter jejuni | 1 | 2007 | 26 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2011 | 880 | 0.020 |
Why?
|
Drug Tolerance | 1 | 2009 | 376 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2011 | 791 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5953 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3595 | 0.020 |
Why?
|
Haemophilus influenzae | 1 | 2007 | 172 | 0.020 |
Why?
|
Family Planning Services | 1 | 2010 | 263 | 0.020 |
Why?
|
Lactates | 1 | 2007 | 432 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2007 | 588 | 0.020 |
Why?
|
Risk Assessment | 2 | 2018 | 23336 | 0.020 |
Why?
|
South Africa | 1 | 2011 | 1731 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2016 | 2055 | 0.020 |
Why?
|
Motivation | 1 | 2016 | 1971 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2011 | 914 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1253 | 0.020 |
Why?
|
Bacteria | 1 | 2016 | 2115 | 0.020 |
Why?
|
Point Mutation | 1 | 2011 | 1624 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2050 | 0.020 |
Why?
|
Medication Adherence | 1 | 2017 | 2063 | 0.020 |
Why?
|
Aged | 4 | 2023 | 163288 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2007 | 1095 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 15520 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1655 | 0.020 |
Why?
|
Community Health Centers | 1 | 2008 | 430 | 0.020 |
Why?
|
Logistic Models | 2 | 2013 | 13409 | 0.020 |
Why?
|
Body Weight | 1 | 2016 | 4671 | 0.020 |
Why?
|
Focus Groups | 1 | 2009 | 1321 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2014 | 1540 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2017 | 6994 | 0.020 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1821 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 5984 | 0.020 |
Why?
|
Pregnancy Trimester, Third | 1 | 2007 | 571 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1888 | 0.010 |
Why?
|
Helicobacter pylori | 1 | 2007 | 383 | 0.010 |
Why?
|
Immunoglobulin A | 1 | 2007 | 995 | 0.010 |
Why?
|
Host-Pathogen Interactions | 1 | 2012 | 1480 | 0.010 |
Why?
|
Sequence Analysis, RNA | 1 | 2011 | 2012 | 0.010 |
Why?
|
Labor, Obstetric | 1 | 2007 | 333 | 0.010 |
Why?
|
Animals | 3 | 2023 | 168768 | 0.010 |
Why?
|
Sexually Transmitted Diseases | 1 | 2009 | 623 | 0.010 |
Why?
|
Immunologic Factors | 1 | 2012 | 1580 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2007 | 1851 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16367 | 0.010 |
Why?
|
Marital Status | 1 | 2003 | 437 | 0.010 |
Why?
|
Streptococcus pneumoniae | 1 | 2007 | 714 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2007 | 1470 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2535 | 0.010 |
Why?
|
Occupations | 1 | 2003 | 517 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2012 | 5096 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2716 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7147 | 0.010 |
Why?
|
Health Promotion | 1 | 2010 | 2205 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18373 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12262 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2003 | 2539 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2006 | 6896 | 0.010 |
Why?
|
Educational Status | 1 | 2003 | 2540 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 4216 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2007 | 4561 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29060 | 0.010 |
Why?
|
United States | 2 | 2011 | 69872 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15535 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2017 | 57776 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 11726 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 15160 | 0.000 |
Why?
|